Fidelis SeniorCare Closes $20.5 Million Equity Financing
Fidelis SeniorCare, Inc., a managed care company that administers Medicare Advantage Special Needs Plans to dual eligibles and individuals living in long-term care facilities, announced the completion of a $20.5 million financing led by Arboretum Ventures, which was joined by other new investors Hopen Life Science Ventures, Renaissance Venture Capital Fund and The Kresge Foundation. Also participating in the financing were existing investors Arcapita, CHL Medical Partners, Highland Capital Partners and Versant Ventures. In conjunction with the financing, Tim Petersen of Arboretum joined Fidelis' board of directors.
Tangent Medical Named Finalist in 2013 American Business Awards
Tangent Medical, an innovator in IV therapy products and creator of the NovaCath™ Integrated IV Catheter System, has been named a finalist in the American Business Awards, sponsored by the Stevie® Awards for two categories including the Best New Product or Service for Health & Pharmaceuticals, and Tech Innovation of the Year (organization with up to 100 employees). Tangent Medical will ultimately be a Gold, Silver or Bronze Stevie® Awards winner in the program.
IntelliCyt Corporation Closes $8 Million in New Financing
IntelliCyt Corporation, a leading provider of assay screening solutions for phenotypic drug discovery, antibody discovery and in vitro testing, announced it has completed an $8 million financing round. The financing was led by new investor Arboretum Ventures with participation from existing investors Prolog Ventures, Verge Fund and New Mexico Community Capital. In connection with the financing, Tim Petersen and George Dunbar from Arboretum Ventures will join IntelliCyt's Board of Directors.
Esperion Therapeutics Presents Full Results of Phase 2 Clinical Trial
Esperion Therapeutics, Inc., a privately-held clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, announced full results of a Phase 2 clinical trial of ETC-1002 in patients with Type 2 diabetes and hypercholesterolemia. The trial met its primary endpoint, demonstrating that ETC-1002 lowered LDL-C by up to 43 percent and was associated with improvements in control of other cardiometabolic risk factors. In addition, ETC-1002 was well tolerated.
As Companies Abandon Cholesterol, an Old Player Re-Emerges
Esperion Therapeutics is featured in an article on Forbes.com discussing Esperion's new cholesterol-lowering pill, ETC-1002, which was show in clinical trials to reduce low-density lipoprotein cholesterol (LDL-C) by as much as 45%.
Esperion Therapeutics Completes $33 Million Preferred Financing
Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, announced that it has completed a $33 million preferred stock financing led by new investor Longitude Capital. Existing investors Aisling Capital, Alta Partners, Domain Associates, Arboretum Ventures and Asset Management also participated in the financing. In connection with this financing, Longitude's Patrick Enright will join Esperion's board of directors.
BAROnova Announces the Results of ENDObesity® I Clinical Trial
BAROnova, Inc., recently presented data from their ENDObesity I clinical trial at the annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting. During the study, which was conducted in Sydney, Australia, obese subjects with a BMI ranging from 30-50 kg/m2 were treated with BAROnova’s weight-loss device, the TransPyloric Shuttle® (TPS®). After six months, patients achieved an average excess weight loss (EWL) of 50%, while subjects in the BMI range of 30-40 kg/m2 achieved an even greater average EWL of 58%.
Advanced ICU Care: A Prescription for Strapped Hospitals
Mary Jo Gorman, a medical doctor in St. Louis, MO, launched Advanced ICU Care, the nation's first "tele-ICU" company, offering around-the-clock monitoring by intensivists for patients in "client" hospitals, in 2004. The company quickly gained a following among community hospitals, such as High Point Regional Health System in High Point, N.C., where Greg Taylor, chief operating officer of the High Point system and a physician, estimates that Advanced ICU has saved him a sum totaling "in the $3 million to $4 million range".
Amerigroup Maryland Members Increase Use of Wellness Services Through MyHealthDIRECT
MyHealthDIRECT, a healthcare IT company offering a web-based software solution that connects patients to healthcare service providers at the most appropriate care setting, announced it has contracted with Amerigroup Community Care of Maryland (Amerigroup Maryland) to develop on-line scheduling with the company's network providers to improve access to wellness care for Amerigroup Maryland members. Data has shown that the members obtaining well-care appointments through Amerigroup Maryland's on-line scheduling connectivity initiative have more than doubled their rate of completion with participating providers.
Sonitus Medical Announces Affirmative Update Regarding Bone Conduction Oral Appliances in American Academy of Otolaryngology-Head and Neck Surgery Policy Statement on Implantable Hearing Devices
Sonitus Medical, Inc., a medical device company that manufactures the world's first and only non-surgical and removable hearing device to transmit sound via the teeth, announced that the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) approved a policy statement on implantable hearing devices that include placement of a bone conduction oral appliance as an acceptable procedure for the relief of appropriate indications (e.g., Single Sided Deafness or Conductive Hearing Loss) when performed by a qualified health care professional. Since hearing aids are medically inappropriate for patients suffering with Single Sided Deafness and Conductive Hearing Loss, the Academy's decision to recognize an intra oral prosthetic hearing device offers these patients a non-surgical and cost-effective treatment option.
BAROnova Secures $27.3 Million in Financing
BAROnova, Inc., a clinical-stage medical technology company developing endoscopically-delivered devices for the chronic treatment of obesity, announced the closing of its Series C financing of $27.3 million. The investment was led by Sante Ventures and Boston Scientific Corporation (NYSE:BSX). Participants included Series B investors ONSET Ventures, Highland Capital Partners and Arboretum Ventures, along with new investors Sante Ventures, Boston Scientific and Lumira Capital. Proceeds will be used to fund a pivotal study of the TransPyloric Shuttle® weight-loss technology to gain U.S. and European regulatory approvals.
Tangent Medical Named Most Innovative Company for the 2013 Business Excellence Awards
Tangent Medical, an innovator in IV therapy products and creator of the NovaCath™ Integrated IV Catheter System, has been named the Most Innovative Company at the 2013 Business Excellence Awards announced recently by ActionCOACH, a leading business coaching first sponsoring the award event.
Esperion Announces Positive Topline Results from a Phase 2 Clinical Trial of ETC-1002 in Patients with Type 2 Diabetes
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo. ETC-1002 therapy was also associated with improvements in control of additional cardiometabolic risk factors in this high-risk, difficult-to-treat patient population. The full data from this Phase 2 clinical trial will be presented at a future scientific meeting.
Tim Mayleben Named President and CEO of Esperion Therapeutics
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, announced the Tim Mayleben has been named president and CEO of the company. Roger Newton, Ph.D., FAHA, who is the founder of Esperion and has been serving as its president and CEO, will become executive chairman and chief scientific officer.
CardioMEMS Wins 2012 Intel Innovation Award
CardioMEMS, Inc., an Atlanta-based medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, announced that it has been honored as the 2012 recipient of the Intel Innovation Award. Founder and CEO Jay Yadav, M.D., was presented with the award during the annual Health IT Leadership Summit held at the historic Fox Theatre in Atlanta, GA.
Inogen recently announced the release of its third-generation portable oxygen concentrator. The Inogen One G3 is both lighter and smaller than its predecessors, while still possessing the same innovative features of the Inogen One G1 and Inogen One G2. The Inogen One products provide 100% of users’ oxygen needs without the need for oxygen tanks or stationary oxygen concentrators.
Advanced ICU Care Monitors Intensive Care Patients Nationally
Six years ago, Creve Coeur, Missouri-based Advanced ICU Care began working with St. Mary's Hospital in Jefferson City to help improve the performance of its intensive-care unit. Since then, St. Mary's ICU has seen significant drops in both mortality rates and patients' average length of stay. Today, Advanced ICU Care uses telemedicine and data analysis to monitor about 25 hospital intensive care units in 12 states, from California to Georgia to Pennsylvania. Since 2006, Advanced ICU Care has grown from 20 employees to more than 150, including 38 physicians.
Tangent Medical Receives FDA Clearance for NovaCath™ Secure IV Catheter System
Tangent Medical, an innovator in IV therapy products, today announced it has received FDA 510(k) clearance for the NovaCath™ Secure IV Catheter System, a product designed to set new standards in peripheral IV catheter design, functionality and performance. The NovaCath™ Secure IV Catheter System integrates a series of next-generation technologies designed to address IV therapy challenges including catheter stabilization, healthcare worker safety, tubing management and patient comfort.
Sonitus Medical Announces its First European Commercialization and the Addition of Two New Executives to the Management Team
Sonitus Medical, Inc., a medical device company that manufactures the world's first non-surgical and removable hearing device to transmit sound via the teeth, announced the global commercialization and a limited market launch in Europe of its SoundBite™ Hearing System. Sonitus also deepened its management team with the recent appointment of Mike Favet as Chief Operating Officer and Jeff Mack as Chief Financial Officer.
It’s clear, despite pre-election uncertainty, that accurate data will be crucial to the future of American healthcare. The name of the game will soon be metrics, as in: If you don’t meet these benchmarks, we’re not going to pay you. Having the best, most up-to-date data not only helps doctors improve care, but it also helps hospitals and clinics run leaner operations. And what Ann Arbor, MI-based startup ArborMetrix is doing, says new CEO Brent Furst, is filtering the noise out of a statistical approach to healthcare.
ArborMetrix Appoints Brett Furst as CEO
ArborMetrix, Inc., a Michigan-based healthcare analytics and software company specializing in the measurement of hospital and specialty-based care, announced the appointment of Brett Furst as CEO. Furst brings more than 22 years of experience in facilitating collaboration through data exchanges and large-scale software solutions in the healthcare, manufacturing and consumer packaged goods industries. Most recently, Brett served as vice president of healthcare at Covisint, a division of Compuware.
The SoundBite system by Sonitus Medical relies on bone conduction—the ability of sound waves to travel from teeth through the bones in the skull. It isn't a hearing aid, which amplifies sound in frequencies where peoples' hearing is diminished. It is aimed instead at people who are completely deaf in one ear, often because of a problem in the cochlea, the spiral-shaped structure in the inner ear. About 8 million Americans were born with single-sided deafness and another 1.5 million developed it later in life.
MyHealthDIRECT, the nation's first and only healthcare scheduling exchange, announced that its board of directors has appointed Tom Cox, a current MyHealthDIRECT board member, to the role of Chief Executive Officer, effective August 1, 2012. Cox will replace MyHealthDIRECT founder Jay Mason, who will remain with the company and continue to serve as a Board Member. Cox joins the company full-time after serving as Chief Operating Officer of Healthways, Inc., the global provider of well-being improvement solutions, where he oversaw sales, marketing and communications, market and delivery operations. Previously, he served as President of Concentra Network Services.
Advanced ICU Care, the nation's largest independent provider of tele-ICU services, announced the opening of a new monitoring center in the heart of New York City to provide expanded 24/7 management of critically ill patients by intensivist physicians to hospitals nationwide. "The New York City Monitoring Center will enable us to better serve our hospital partners and patients as well as to support our growth and the increased demand for comprehensive tele-ICU programs and consulting services," said Mary Jo Gorman, M.D., MBA, Chief Executive Officer of Advanced ICU Care
KFx Medical Receives FDA 510K Clearance for Smaller AppianFx® Tissue Fixation Anchor
KFx Medical Corporation announced it has received 510(k) clearance from the Food and Drug Administration (FDA) for its 5mm AppianFx® Tissue Fixation Anchor. Tate Scott, President and CEO of KFx said this new anchor enables KFx to expand into the rapidly growing foot and ankle repair and reconstruction market, as well as other applications requiring smaller implants.
MyHealthDIRECT Strengthens Board of Directors, Wins HHS Innovation Award
MyHealthDIRECT, the nation's first and only healthcare scheduling exchange, announced the addition of two health industry veterans, Tom Cox and Jacque Sokolov, MD, to the company's Board of Directors. This announcement comes as the Company was awarded first place on June 5th at the "Discharge Follow-Up Appointment Challenge" sponsored by the Department of Health and Human Services Office for the National Coordinator for Health IT. MyHealthDIRECT's Healthcare Scheduling Exchange (sm) is a web-based platform that allows patients and caregivers to search for, book and confirm doctor appointments.
Uptake Medical Announces Positive 12-month Outcome Data for InterVapor Therapy
Advanced emphysema patients who underwent minimally invasive InterVapor™ (bronchoscopic thermal vapor ablation) experienced sustained improved lung function and quality of life outcomes one year after undergoing treatment, according to new data presented today at the meeting of the American Thoracic Society (ATS) in San Francisco, CA. The InterVapor procedure, pioneered by U.S.-based Uptake Medical, involves catheter-based application of precise amounts of thermal vapor to specific areas within an emphysema patient’s airways, to achieve lung volume reduction.
Sonitus Medical Closes $25 Million Series D Financing
Sonitus Medical, Inc., a medical device company that manufactures the world's first non-surgical and removable hearing device to transmit sound via the teeth, announced that it has closed a $25 million Series D round of venture capital funding. Abingworth, an international investor dedicated to life sciences, led the round and was joined by all current venture capital investors.
Noah Rosenberg, MD, Joins Esperion Therapeutics as Chief Medical Officer
Esperion Therapeutics, Inc. announced the appointment of Noah Rosenberg, MD, as its chief medical officer (CMO). Dr. Rosenberg will lead the Esperion clinical advisory board and will develop and manage the company’s clinical programs. He will also manage the regulatory review process for the company’s innovative investigational therapies to prevent, treat and reverse cardiovascular and metabolic diseases.
Inogen Secures $20 Million in Financing
Inogen, Inc., a manufacturer and accredited homecare provider of oxygen therapy equipment and services, announced that it has secured $20 million in equity financing from a group of investors led by Novo A/S. The funds will support Inogen's continued growth and build upon its position within the homecare community as a leading manufacturer and provider of innovative oxygen technology.
Esperion Announces Positive Phase 2 Clinical Trial Results for ETC-1002
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced positive results from a Phase 2 clinical trial for ETC-1002. This novel small molecule activator of AMP Kinase has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism. Results were presented in an oral presentation at the 2012 American College of Cardiology meeting in Chicago.
André de Bruin Appointed Chair of NxThera Board of Directors
NxThera, Inc., a St. Paul-based, privately held medical device company that developed the Rezum™ vapor ablation system to treat a variety of endourology conditions, beginning with benign prostatic hyperplasia (BPH), announced the appointment of André de Bruin as chair of the company's board of directors. Mr. de Bruin has served as a director of NxThera since November 2009, and has more than 35 years of global healthcare industry experience spanning the medical device, bio-pharmaceutical and diagnostics markets.
Uptake Medical Announces Successful Completion of Series C Financing
Uptake Medical® announced that it has closed on a Series C funding round. The round was led by Singapore-based Crescent Point Group, with existing investors, Maverick Capital, ONSET Ventures, GBS Venture Partners, WRF Capital, Arboretum Ventures and Affinity Capital, making additional investments. Sami Sindi, Crescent Point managing partners, will join the Uptake Medical board of directors.
Uptake Medical Announces TGA Approval of InterVapor for Patients with
Uptake Medical® announced that it received Australian Therapeutic Goods Administration (TGA) approval for its InterVapor™ System for endoscopic lung volume reduction for the treatment of severe emphysema. Clinical efficacy of InterVapor has been established by the multi-center VAPOR trial which showed a reduction in lung volume as well as statistical and clinical significance in lung function improvement (FEV1) and health-related quality of life (SGRQ) at six months
Uptake Medical Announces First Commercial Use of InterVapor for Patients with Severe Emphysema
Uptake Medical® announced the first commercial use of the InterVapor™ System for endoscopic lung volume reduction in a patient with sever emphysema. The patient successfully underwent treatment with InterVapor, the first endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body's natural healing processes without leaving foreign materials in the lung. The patient was treated by the team at the Thoraxklinik in Heidelberg, Germany, which is led by Professor Dr. Felix Herth and is recognized as a leading institution for pioneering new therapeutic options for people with emphysema.
Trident Capital, Inc. Invests in Advanced ICU Care
Advanced ICU Care, the nation's largest independent provider of tele-ICU programs, announced that it has closed a new round of equity funding. The financing was led by Trident Capital, Inc., and includes existing investors, Versant Ventures, Arboretum Ventures, and Catalyst Capital. John Reardon, Managing Director with Trident Capital, will join the Advanced ICU Care Board of Directors.
Cervilenz Inc. Receives CE Mark and Additional International Patents
Cervienz Inc recently received it's CE Mark and ISO 13485 Certification for the CerviLenz® Device. This innovative medical device is used to measure vaginal cervical length to help obstetricians identify and manage pregnant women at high risk for premature birth. Cervilenz Inc. also added to its already robust patent portfolio for the device. The company now holds 12 issued patents, including 5 in the United States, 5 in Europe, 1 in Japan and 1 in Turkey. Ten additional patent applications are pending.
Tangent Medical Closes $4.5 Million Series A Financing
Tangent Medical Technologies, Inc., a development stage medical device company, announced the completion of a $4.5 million Series A equity financing co-led by Arboretum Ventures and Flagship Ventures. Also participating in the financing were Osage Ventures and several angel investors responsible for the initial seed funding of the company. Tangent plans to use the Series A proceeds for regulatory filings and commercial launch of the company's lead product, the NovaCath™ Closed IV Catheter System.
Mary Jo Gorman Selected for the 2011 Ernst & Young Entrepreneurial Winning Women™ Program
Mary Jo Gorman, M.D., chief executive officer and founder of Advanced ICU Care, has been named one of ten winners of the 2011 Ernst & Young Entrepreneurial Winning Women competition, and the first winner from the state of Missouri. The annual competition and leadership program honors women founders or cofounders of businesses whose success demonstrates the creativity, tenacity and conviction necessary to realize their companies' full potential and the drive to achieve market leadership.
PathCentral, Inc. Appoints Todd S. Barry, M.D., PH.D. Medical Director
PathCentral, Inc., the first and only company focused exclusively on the success of the community pathologist, announced the appointment of Todd Barry, M.D., Ph.D., to the post of Medical Director. Dr. Barry brings nearly 15 years of professional experience to the company, having previously served as a hematopathologist and medical director at Clarient (now GE) and director of molecular pathology and hematopathology at PhenoPath Laboratories.
MyHealthDIRECT Signs Contract with Health Partners of Philadelphia
MyHealthDIRECT announced it has signed a contract with Health Partners of Philadelphia, a not-for-profit health plan, which will use MyHealthDIRECT's web-based scheduling service solution to enable increased access to care and enhanced care coordination for its 170,000 members. The initial launch of the program will include ten physician practices from Health Partners' robust provider network.
CardioMEMS, Inc. Presented the Phoenix 2011 Most Promising New Product Award
CardioMEMS, Inc., an Atlanta-based medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, announced that it has been honored with the prestigious Phoenix 2011 Most Promising New Product Award for the CardioMEMS Champion® Heart Failure Monitoring System.
Uptake Medical Receives CE Mark for InterVapor-Endoscopic Lung Volume Reduction
Uptake Medical announced it has received the CE Mark (Conformité Européenne) for the InterVapor™ System - the first endoscopic lung volume reduction system for the treatment of severe emphysema the uses the body's natural healing processes without leaving foreign materials behind. The CE Mark will allow Uptake Medical to commercialize InterVapor in key markets within the European Community.
NxThera Completes $21.6 Million Series B Financing
NxThera, Inc., a St. Paul-based, privately held medical device company developing its innovative and proprietary Rezum™ vapor ablation system to treat a variety of endourology conditions, beginning with benign prostatic hyperplasia (BPH), announced the recent completion of a $21.6 million round of Series B equity financing (a portion of which investment will be funded upon the achievement of certain development milestones). The company plans to use this capital to seek the necessary regulatory approvals to undertake its pivotal Rezum™ BPH clinical study internationally and in the U.S., and begin development of additional endourology applications.
Inogen Acquires Breathe Oxygen Services
Inogen, Inc., a leading oxygen therapy services provider, has successfully completed the acquisition of Breathe Oxygen Services (BOS), a homecare respiratory services company located outside of Nashville, TN. Inogen currently services thousands of oxygen therapy patients across the country and looks forward to providing the same outstanding service and support to BOS patients.
The Future of Tele-ICUs: An Insider's Perspective
Mary Jo Gorman, M.D., is the CEO of Advanced ICU Care, a medical service company headquartered in St. Louis, MO., which provides high-quality care to patients in the intensive care unit. In this article, Mary Jo explains her motivation behind bringing telemedicine technology to life through Advanced ICU Care and the benefits tele-ICUs have on patient care and ICU mortality rates in participating hospitals.
Sonitus Medical Receives Second FDA Clearance for SoundBite Hearing System
Sonitus Medical, Inc., a medical device company that manufactures the world's first non-surgical and removable hearing device to transmit sound via the teeth, announced that it has received an additional FDA clearance for its SoundBite Hearing System. The FDA 510(k) clearance for Conductive hearing loss is the second for the SoundBite prosthetic device and marks another significant milestone for the company.
NxThera, A High-Horsepower Treatment
Michael Hoey says his father is the inspiration behind the medical device firm he founded. In 1990 his father, Francis, was diagnosed with prostate cancer. It took about 10 years, but Michael Hoey eventually hit on an idea he thinks could significantly improve treatment of prostate conditions: using vapor to treat them without impacting the rest of the body. His company, St. Paul-based NxThera, closed on $11.5 million in financing in the first quarter of 2011.
Esperion Announces Results from Phase 1 Study and Four Preclinical Studies for ETC-1002
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago. In the Phase 1 study, treatment with ETC-1002 was shown to be safe and well tolerated and to significantly reduce LDL-C levels in subjects with mild dyslipidemia.
Life Magnetics, Inc. Names Jeff Williams as CEO, and Sundu Brahmasandra as President
Life Magnetics, Inc., a spin-out from the University of Michigan engaged in the development of novel in vitro diagnostic tests, announced the appointment of Jeffrey S. Williams as CEO, and Sundu Brahmasandra, PhD, as President. Mr. Williams was most recently President and CEO of Accuri Cytometers, Inc. leading the company through significant revenue growth culminating in the sale of the company to Beckton, Dickinson & Company in March 2011. Dr. Brahmasandra was a Co-Founder of HandyLab, Inc., where he served as V.P. Product Development, leading the successful development and launch of the company's molecular diagnostics products.
Life Magnetics Draws High-Powered Team
Medical device company Life Magnetics, Inc., announced that two of the biggest stars of local high-tech entrepreneurship, Jeffrey Williams and Sunu Brahmasandra, will head the company's commercialization efforts. The company's business model is based on drastically speeding up the time it takes to figure out what is making a patient sick. Today, it takes three to five days for a tissue or fluid sample to be cultured to the point where a pathogen can be identified. Life Magnetics hopes to reduce that to a few hours, with a huge savings in the cost of hospital stays and a reduction in mortality.
Wellfount Corporation Completes $6 Million Series A Financing
Wellfount Corporation announced that it has closed a Series A investment round with a $6 million funding commitment from one of the nation's leading healthcare venture capital firms, Arboretum Ventures. The investment provides significant support to Wellfount's continued nationwide service expansion and roll-out of its innovative pharmacy distribution and dispensing technologies.
MyHealthDIRECT Receives $4 Million in Series B Investment Funding
MyHealthDIRECT announced that it has closed its Series B investment round with $4 million in funding from two of America's leading healthcare venture capital firms, Arboretum Ventures and Chrysalis Ventures. Founded in 2005, MyHealthDIRECT is a web-based access management system that broadly and seamlessly connects patients to healthcare appointments throughout a community or network.
BD Completes Acquisition of Accuri Cytometers, Inc.
BD (Becton, Dickinson and Company)(NYSE: BDX), a leading global technology company, announced the completion of its acquisition of Accuri Cytometers, Inc., an Ann Arbor, Michigan-based company that develops and manufactures personal flow cytometers for researchers.
NxThera Closes $12.6 Million of Series B Financing
NxThera, Inc., a St. Paul-based, privately held medical device company developing an innovative and proprietary vapor ablation therapy to treat a variety of endourology conditions, beginning with benign prostatic hyperplasia (BPH), announced completion of a $12.6 million round of Series B equity financing. American Medical Systems, Inc. (AMS) led this phase of NxThera's Series B investment and was joined by the company's existing investors, Arboretum Ventures, Aberdare Ventures and GDN Holdings.
VasoNova Inc. Receives 510(k) Clearance for Expanded Use of VPS Technology
Teleflex Incorporated (NYSC: TFX), a leading global provider of medical technology products, announced that its VasoNova Inc. subsidiary has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the company's VPS™ peripherally inserted central catheter tip location technology as an alternative to chest x-ray or fluoroscopy in adult patients when the guidance indicator shows a blue bullseye.
Scott Huennekens Elected to Uptake Medical Board of Directors
Uptake Medical Corp., a developer of medical technologies for the non-surgical treatment of lung diseases including emphysema, announced that Scott Huennekens, President and CEO of Volcano Therapeutics, (NASDAQ: VOLC) has joined the company's Board of Directors. Mr. Huennekens has served as President, CEO and Director of Volcano since April 2002.
CardioMEMS Sensor Significantly Reduces Heart Failure Hospitalizations
The CHAMPION clinical trial, published online in The Lancet, demonstrated a 30% reduction in the primary efficacy endpoint of heart failure hospitalization rates at 6 months, and a 39% reduction in heart failure hospitalization rates at 15 months for heart failure patients whose treatment was guided by pulmonary artery pressures obtained through a miniature, wireless sensor, compared to control patients receiving standard heart failure treatment. The trial also met all of its safety and secondary efficacy endpoints.
BD Announces Agreement to Acquire Accuri Cytometers, Inc.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that it signed a definitive agreement to acquire Accuri Cytometers, Inc., an Ann Arbor, Michigan-based company that develops and manufactures personal flow cytometers for researchers. Consistent with BD's acquisition strategy, the acquisition would expand BD's presence into the emerging affordable personal flow cytometer space.
Life Magnetics Inc. Becomes the First Tenant of the University of Michigan's New Business Incubator
Life Magnetics recently signed a deal to become the first tenant of the U-M Technology Transfer Office's new 16,000-square-foot business incubator, which is housed in a building at the former Pfizer complex. Life Magnetics is renting 1,400 square feet of lab space at the Venture Accelerator facility on what U-M is calling its North Campus Research Complex. The space gives Life Magnetics access to high-tech equipment and intellectual resources from employees of the Tech Transfer Office and Business Engagement Center, which are collocated with the incubator at the facility.
Teleflex Acquires VasoNova Inc.
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technology products, announced it has acquired privately-held VasoNova Inc. Based in Menlo Park, CA, VasoNova has developed a unique central venous catheter navigation technology that allows for real-time accurate confirmation of placement of peripherally inserted central catheters and central venous catheters in the lower one third of the superior vena cava, the optimal position for catheter tip location.
Esperion Therapeutics Initiates Phase 2 Clinical Study
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate. ETC-1002 is a novel small molecule compound that has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism.
Life Magnetics, Inc. Adds Jeff Williams to its Board of Directors
Life Magnetics, Inc., a spin-out from the University of Michigan, engaged in the development of novel in vitro diagnostic tests, announced the addition of Jeffrey S. Williams to its Board of Directors. Mr. Williams is currently President and CEO of Accuri Cytometers, Inc. based in Ann Arbor, Michigan.
Uptake Medical Names J.C. MacRae as Chief Financial Officer
Uptake Medical, the leading developer of medical technologies for interventional emphysema therapy, announced that J.C. MacRae has joined the company as its vice president and chief financial officer. MacRae was most recently a member of the senior management team at CoreValve Inc., a catheter-based heart valve replacement company, recently acquired by Medtronic, serving as chief financial officer and managing director of CoreValve Europe, BV.
PathCentral Secures $10 Million Series B Investment
PathCentral, an Irvine, California-based anatomic pathology services company, announced it has raised $10 million in Series B financing. The proceeds will be used to support the company's growth initiatives, continue to enhance its web-based laboratory information system (LIS), deploy a field sales force, and build out its esoteric cancer diagnostics laboratory. Okapi Venture Capital, Arboretum Ventures, and Baird Venture Partners co-led the round.
Steven Kesten, M.D., Joins Uptake Medical as Vice President and Chief Medical Officer
Uptake Medical Corp., a developer of medical technologies for the nonsurgical treatment of lung diseases including emphyseam, announced that Dr. Steven Kesten will join the company as its vice president and chief medical officer. Dr. Kesten joins Uptake Medical with over 20 years experience in pulmonary medicine including academic research and clinical leadership in the pulmonary industry.
Uptake Medical Presents VAPOR Clinical Trial Data
Uptake Medical Corp., a developer of medical technologies for the non-surgical treatment of lung diseases including emphysema, announced that they presented data from their VAPOR clinical trial for emphysema at the 2010 ERS meeting in Barcelona, Spain. The VAPOR clinical trial evaluates the Company's proprietary non-implant InterVapor™ System for the treatment of patients suffering from heterogeneous emphysema.
National Cancer Institute Awards Contract to Asterand
Asterand plc (LSE:ATD), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research announced that it has been awarded a 5-year, up to $24.3 million contract with the National Cancer Institute (NCI) to supply clinically annotated human biospecimens for The Cancer Genome Atlas (TCGA) project.
VasoNova Inc. Announces Strategic Partnership with Navilyst Medical Inc.
VasoNova Inc. announced a strategic partnership with Navilyst Medical Inc. to distribute its VasoNova™ Vascular Positioning System™ VPS™ central venous catheter navigation technology.
St. Jude Medical Signs Equity Investment and Option to Purchase Agreement with CardioMEMS
St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, and privately-held CardioMEMS today announced that they have reached an agreement under which St. Jude Medical will make a $60 million equity investment in CardioMEMS, a medical device company that has developed a wireless sensing and communication technology to assess cardiac performance. The agreement provides St. Jude Medical an immediate 19 percent ownership in CardioMEMS and the exclusive option to acquire the company for an additional payment of $375 million during the period that extends through the completion of certain commercialization milestones.
Arboretum Ventures Announces Series A Investment in Life Magnetics, Inc.
Arboretum Ventures, a healthcare venture capital firm specializing in early-stage company investments, announced the completion of the Series A preferred stock financing with Life Magnetics, Inc. Life Magnetics is developing a desktop in vitro diagnostic device and disposable cartridge assay for rapidly testing bacterial infections.
Accuri Cytometers Completes $6 Million Series E Financing
Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse. Accuri plans to use the proceeds from the Series E financing to support expansion of the Accuri C6 Flow Cytometer® System into the clinical in vitro diagnostics (IVD) market.
Uptake Medical Completes $17.5 Million Series B Financing
Uptake Medical, a privately held interventional pulmonology company, announced that it has concluded its Series B financing from an investment group led by Maverick Capital, a new investor. The company's existing investors, which include GBS Venture Partners, Onset Ventures, WRF Capital, Arboretum Ventures and Affinity Capital, also participated in the financing. The company plans to use this capital to obtain the CE mark and introduce their unique proprietary Bronchoscopic Thermal Vapor Ablation (BTVA) technology outside of the U.S. The company also has begun it's approval cycle with the FDA in the U.S.
CerviLenz Announces Addition of Senior Level Financial and Operational Expertise
CerviLenz Inc. announced the addition of an executive to its senior management team. Federica O'Brien joins the company in the new position of Chief Financial Officer/Chief Operating Officer. The Cervilenz device is a simple and cost effective tool that measures cervical length objectively to help clinicians identify pregnant women at risk of preterm birth.
TransGenRx Protein Therapeutics Technology to Support Research at Esperion
Esperion Therapeutics, a privately help biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.
Esperion Therapeutics and Cleveland Clinic Establish Collaboration
Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced the establishment of a collaborative research agreement with Cleveland Clinic. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.
CardioMEMS Completes CHAMPION Clinical Trial Study
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, announced its CHAMPION trial met its primary efficacy endpoint with a 30% reduction in heart failure hospitalization rates at 6 months in heart failure patients whose treatment was guided by pulmonary artery pressures obtained through a miniature, permanent wireless implant.
Delphinus Receives $8 Million in Financing
The Barbara Ann Karmanos Cancer Institute announced that its spin-off company Delphinus Medical Technologies, LLC, has secured $8 million in venture capital to start the commercialization process of SoftVue, an alternative to mammography. SoftVue's lead investor is Arboretum Ventures; Beringea, LLC co-led the deal through its InvestMichigan Growth Capital Fund and was joined by North Coast Technology Investors and the Wolverine Venture Fund.
CerviLenz Announces Availability of its Device
CerviLenz Inc. announces the availability of its innovative device, CerviLenz® - a new tool for preterm labor triage. CerviLenz measures vaginal cervical length objectively, the first and only device of its kind. CerviLenz helps obstetricians, nurse-midwives, and L&D nurses assess and monitor women with signs or symptoms of preterm labor.
CardioMEMS Raises Additional Capital
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, announced the completion of a $37.9 million financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
CerviLenz Device Making Headlines
A device coming to market this spring by a Chagrin Falls, Ohio company improves how doctors evaluate the risk of perterm labor. CerviLenz Inc., a manufacturer and distributor of a disposable device used to predict the risk of preterm birth in pregnant women, has been ramping up for its launch this year with a $4 million infusion of capital in May 2009 from Chrysalis Ventures and Arboretum Ventures.
Asterand Completes Acquisition of BioSeek
Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, announced it has completed its acquisition of BioSeek, Inc., a pioneer in the application of predictive human biology to drug discovery through its unique human primary cell based disease models.
Accuri Cytometers Announces Senior Management Transition
Accuri Cytometers Inc., a life science company marketing innovative bench-top flow cytometer systems, announced that co-founder and CEO Jennifer Baird has resigned and will be replaced by Jeffrey S. Williams, most recently President and CEO of HandyLab Inc., an Ann Arbor-based molecular diagnostics company acquired by Becton Dickinson for $275 million in November 2009.
Becton, Dickinson and Company Completes $275 million Acquisition of HandyLab
BD (Becton, Dickinson and Company) (NYSE:BDX) announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.
Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.
Asterand: A Medical Pioneer in Detroit
Asterand wants to turn the city of Detroit into a world leader in medical and pharmaceutical research. Located inside Detroit's TechTown business incubator, Asterand is a human-tissue bank that collaborates with pharmaceutical companies on drug discovery and development. Asterand went public on the London Stock Exchange in 2006, after it merged with U.K.-based Pharmagene.
Ministry Health Care's Saint Clare's Hospital in Weston, WI first started looking into virtual ICU to access a larger number of intensivists that the hospital could recruit on its own. With only one intensivist on staff, Saint Clare's turned to St. Louis based Advanced ICU Care to get the 24/7 support it needed.
Uptake Medical Presents Data from Phase II Clinical Trial for Patients with Heterogeneous Emphysema
Uptake Medical Corp., a developer of medical technologies for the non-surgical treatment of lung diseases including emphysema, announced that data will be presented from their most recent clinical trial for emphysema at the 2009 ERS meeting in Vienna, Austria. The phase II clinical trial evaluates the Company's proprietary minimally invasive Bronchoscopic Thermal Vapor Ablation™ (BTVA™) technology for the treatment of patients suffering from heterogeneous emphysema.
KFx Medical Awarded Key Patent for Knotless Tissue Fixation
KFx Medical, developing clinically relevant solutions to rotator cuff repair, announced that it was awarded a US Patent No. 7,585,311 by the United States Patent and Trademark office. The key patent covers a broad range of methods used to perform surgical knotless tissue fixation, including the double row tissue repair technique used to restore the rotator cuff to its correct anatomic position.
CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial
CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, announced the completion of a $22.1 million financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.
Accuri Cytometers Completes $4 Million Series D Financing
Accuri Cytometers, Inc., a life science company developing and marketing revolutionary high performance cell analysis systems, announced the completion of a $4 Million Series D financing. The financing includes current investors Fidelity Biosciences, Flagship Ventures, Baird Venture Partners and Arboretum Ventures, as well as the InvestMichigan! Program co-managed by Credit Suisse.
HandyLab Announces Exclusive Collaboration with Becton, Dickinson and Company
BD Diagnostics, a segment of BD and HandyLab, Inc. announced that they have entered into an exclusive agreement for BD to commercialize its molecular assays on a new BD MAX system in development using HandyLab's recently launched Jaguar instrument. Released in November 2008, HandyLab's Jaguar system is the first fully integrated bench-top molecular diagnostic system to provide hands-off operation.
Mary Jo Gorman named by Modern Healthcare as one of its Top 25 Women in Healthcare
Modern Healthcare has named Mary Jo Gorman, MD, Chief Executive Officer of Advanced ICU Care to its list of the "Top 25 Women in Healthcare". The biennial list honors female healthcare executives who are making a positive difference in healthcare. Advanced ICU Care is a medical service company that provides high-quality remote critical care to patients in the intensive care units (ICU) of community hospitals.
CerviLenz Inc. Raises $4 Million in Venture Funding
CerviLenz Inc., a manufacturer and distributor of a disposable device used to predict the risk of preterm birth in pregnant women, announced that is has raised $4 million in the company's initial round of venture funding. Ann Arbor, MI based Arboretum Venture led the round with Louisville, KY based Chrysalis Ventures co-investing in the financing.
VasoNova Exits Stealth After Catheter Clearances
VasoNova Inc. recently secured two more Food and Drug Administration device clearances and will launch its vascular navigation system this summer. VasoNova has been developing the Vascular Positioning System which uses Doppler ultrasound and electrocardiography technology for the precise placement of peripherally inserted central catheters or PICCs.
HandyLab Grants Qiagen License to Sample Technology
HandyLab Inc, dedicated to the development, manufacture and sale of novel molecular diagnostic products, announced that QIAGEN N.V. has licensed HandyLab extraction technology for use at part of QIAGEN's sample technology solution designed for use in combination with QIAGEN's HPV assays on its QIAensemble screening and QIAsymphony random access platforms.
KFx Medical Develops PASTAFx System
KFx Medical Corporation, developing clinically relevant solutions to rotator cuff repair, announced the PASTAFx Anchor System used in the repair of partial rotator cuff tears, including Partial Articular Sided Tendon Avulsion (PASTA) tears. PASTAFx was introduced at the American Association of Orthopedic Surgeons (AAOS) in Las Vegas on February 25 - 27, 2009.
Johnson & Johnson Acquires HealthMedia, Inc.
As an initial step in the creation of a wellness and prevention business platform, Johnson & Johnson announced it has acquired HealthMedia Inc., a privately held company that creates web-based behavior change interventions. HealthMedia, located in Ann Arbor, Michigan, combines advanced technology and behavioral science to effectively emulate a health coach via the web.
Uptake Medical Presents Data From Safety & Feasibility Clinical Trial
Uptake Medical Corp., a developer of medical technologies for the minimally-invasive treatment of lung diseases including emphysema, announced it will present data from their first safety & feasibility clinical trial at the 2008 CHEST meeting in Philadelphia. The trial was a phase I study for the company's proprietary minimally-invasive Bronchoscopic Thermal Vapor Ablation (BTVA) treatment for patients suffering from heterogeneous emphysema with upper lobe predominance.
BAROnova Secures Investment From Allergan, Inc.
BAROnova, Inc. announced the closing of its Series B financing of $7.5M, led by a strategic investment from Allergan, Inc. Series A investors Arboretum Ventures, Highland Capital Partners and ONSET Ventures also participated in this round of financing. BAROnova will use the proceeds to continue the clinical development of their non-surgical, non-pharmacologic TransPyloric Shuttle (TPS) weight-loss technology, and to fund ongoing operations.
Advanced ICU Care Named Among Top 100 Best Places to Work
Advanced ICU Care, a healthcare services company employing telemedicine technology to enable remote care for hospital ICU patients, was named one of the top 100 best places to work in healthcare by Modern Healthcare. This special supplement recognizes workplaces in healthcare that enable employees to perform at their optimum level to provide patients and customers with the best possible care and services.
HandyLab Inc. Announces the Release of Jaguar Automated PCR System
HandyLab Inc., a developer of novel molecular diagnostic testing products, announces the release of the Jaguar Automated PCR System. This Real-Time PCR System integrates sample preparation, nucleic acid extraction, and microfluidic amplification and detection into a single instrument. Two to twenty-four tests can be run in 45 to 90 minutes from a raw patient sample.
HandyLab Inc. Closes on $19.5M
HandyLab Inc., dedicated to the development, manufacture and sale of novel molecular diagnostic products, announced it has closed on a $19.5M round of venture capital. Two new venture capital firms joined this round, Chicago-based Lurie Investments Inc. and Midland-based Dow Ventures. These new investors joined previous investors, Pfizer Strategic Investments Group, Ardesta LLC, EDF Ventures and Arboretum Ventures LLC, who also participated in the round of funding.
Accuri Cytometers Completes $13M Series C
Accuri Cytometers Inc., a life science company developing revolutionary bench-top flow cytometer systems, announced the completion of a $13M Series C financing led by Fidelity Biosciences and Flagship Ventures. Current investors, Baird Venture Partners and Arboretum Ventures, also participated in the financing. Bahaa Fam, Venture Partner, Fidelity Biosciences and Harry Wilcox, Partner, Flagship Ventures, will join Accuri's Board of Directors.
Advanced ICU Care Raises $5M in Funding
Advanced ICU Care, a healthcare service company employing telemedicine technology to enable remote care for hospital ICU patients, announced the closing of a $5M Series B financing led by Versant Ventures. Other participants include existing investors Catalyst Capital Management, Arboretum Ventures and individual investors. Advanced ICU Care also announced that Barbara Lubash, managing director of Versant Ventures, has joined the company's Board of Directors.
Advanced ICU Care News - Specialists Staff Small Town ICUs
Advanced ICU Care contracts with intensive care units, such as the one at St. Mary's Health Center in Jefferson City, MO., to provide intensivists services remotely through monitors, television screens and other technologies. Since implementing AICU Care's program, St. Mary's has seen cardiac arrests in the ICU fall 67 percent, and the number of patients leaving the hospital alive improve by 24 percent.
Uptake Medical Announces Completion of Pilot Safety and Feasibility Clinical Trial
Uptake Medical Corp, a developer of medical technologies for the treatment of lung diseases including emphysema, announced it has successfully completed patient enrollment in a phase I safety and feasibility clinical trial conducted at two centers in Australia.
Esperion Therapeutics Completes $22.75M Series A
Esperion Therapeutics, Inc., a biopharmaceutical company focused on the discovery and development of compounds to treat cardiovascular and metabolic disease, announced it has been launched as a privately held, independent enterprise. The financing was co-led by Aisling Capital, Alta Partners and Domain Associates and also included participation by Arboretum Ventures.
Accord Biomaterials Closes $1M Series A
Accord Biomaterials, a developer of nitric oxide medical device coatings, announced the closing of a $1M Series A financing led by Arboretum Ventures. Sigvion Capital and the University of Michigan's Wolverine Venture Fund joined Arboretum to fund Accord whose core technology was developed at the University of Michigan and MC3 Corporation.
Online Health Counseling Grows HealthMedia
HealthMedia, a global leader in online delivery of behavior change interventions, saw health care license revenue growth jump 100 percent in the third quarter of 2007. HealthMedia's technology helps patients with everything from wellness regimens to taking their medication.
CardioMEMS Closes Series E Financing and Appoints New CFO
CardioMEMS Inc., a developer of wireless pressure sensors for the management of cardiovascular disease, announced the closing of its $33 million Series E Preferred Stock financing. The Board of Directors of CardioMEMS also announced that it has appointed Daniel H. Bauer as Chief Financial Officer of the Company.
CardioMEMS Announces Start of CHAMPION Pivotal Study
CardioMEMS Inc., a developer of wireless pressure sensors for the management of cardiovascular disease, announced that its wireless pressure sensor for heart failure (HF) monitoring was successfully implanted in two patients at Saint Thomas Hospital in Nashville, Tennessee. These patient implants mark the initiation of the CHAMPION pivotal clinical study.
Mirabilis Medica Closes Series A Extension
Mirabilis Medica, a privately-held medical device company announced the closing of a $10.5 million extension to its series A financing which was originally led by Charter Life Sciences and vSpring Capital last year. The series A extension was led by Arboretum Ventures, and included Split Rock Partners, Dow Venture Capital and an individual investor.
KFx Medical Corporation Closes Series B Financing
KFx Medical Corporation, a developer of minimally invasive percutaneous repair systems for rotator cuff repair, has closed a Series B financing. Investors in the $10M Series B round include lead investor Alloy Ventures, and returning investors Charter Life Sciences L.P., Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners.
Accuri Cytometers Adds Two Executives to its Board of Directors
Accuri Cytometers, Inc., a life science company developing bench-top flow cytometer systems, announced the appointment of Daniel J. Calvo and George W. Dunbar to its Board of Directors. Daniel Calvo is currently President and CEO of Assay Designs, and George Dunbar is currently President, CEO and a Director of Aastrom Biosciences.
HealthMedia will Offer Online Programs for Free
HealthMedia Inc., a global leader in online delivery of behavior change interventions, will offer seven of its programs for free to Washtenaw County, Michigan residents for the next 12 months. Residents will be able to access HealthMedia's web-based programs that help people manage health behavior in areas such as smoking, weight loss or diabetes management.
Accuri Cytometers Announces Completion of Series B Financing
Accuri Cytometers Inc., a medical equipment company developing bench-top flow cytometer systems, announced the completion of a $5 million Series B financing led by Baird Venture Partners (BVP). Arboretum Ventures co-led the financing, with both firms being new investors in Accuri.
CardioMEMS Announces FDA Clearance
CardioMEMS Inc., a developer of wireless pressure sensors for the management of cardiovascular disease, announced March 28, 2007 Food and Drug Administration (FDA) clearance of the EndoSure AAA Wireless Pressure Measurement System for measuring intrasac pressure during thoracic aortic aneurysm repair.
HealthMedia’s Health Risk Assessment Now Available
HealthMedia, Inc., the global leader in scalable behavior change interventions, announced that the nation’s leading integrated health plan Kaiser Permanente, has selected HealthMedia Succeed as its program-wide Health Risk Assessment (HRA) solution across all national regions.
Asterand Offers Researchers Internet Access to RNA
Asterand, a leading provider of human tissue and related services, announced that it is offering research scientists access to human RNA samples via the internet to speed drug discovery. RNA analysis is an effective way of differentiating between the diseased state and normal state of tissues.
Inogen Secures $22 Million in Financing
Inogen, a leading developer of long-term oxygen therapy technologies, announced February 15, 2007 that it has secured $22 million in funding from first time investors Arboretum Ventures and Novo A/S, who joined existing investors Versant Ventures, Accuitive Medical Partners and Avalon Investments.
CardioMEMS Announces First Patient Implant of Wireless Pressure Sensor
CardioMEMS Inc., a developer of wireless pressure sensors for the management of cardiovascular disease, announced that its wireless pressure sensor for heart failure monitoring was successfully implanted in two patients at Okalahoma Heart Hospital under the direction of Philip Adamson, MD, Director of the Heart Failure Institute.
HealthMedia Acquires MySelfHelp.com
HealthMedia, a global leader in online delivery of behavior change interventions, announced that it has acquired MySelfHelp.com. MySelfHelp.com offers behavioral health programs for treating depression and insomnia. The acquisition will enhance the product line of HealthMedia, allowing it to provide a more comprehensive set of programs to its customers.
NeoGuide Systems Closes Series C Financing
NeoGuide Systems announced that it raised $25 million in its Series C Round. NeoGuide has developed a computer-assisted colonoscopy system designed to enhance physician control, making the procedure faster and less painful for the patient. The company received FDA clearance for the device earlier this year and expects to begin commercialization in 2007.
NeoGuide Names New President and Chief Executive Officer
NeoGuide Systems Inc., a developer of technology to prevent and treat colorectal cancer, named Austin Noll its new President and Chief Executive Officer. Noll has nearly twenty years of experience in the medical device industry, most recently as Senior Vice President of Marketing and Business Development for Medtronic Neurologic Technologies.
CardioMEMS Closes Series D Financing, Appoints New CFO
CardioMEMS Inc., a developer of wireless pressure sensors for the management of cardiovascular disease, announced that it raised $22.6 million in equity funding. The Board of Directors also announced that it has appointed Harold W. Ingalls as Chief Financial Officer.
CardioMEMS Wins Frost and Sullivan Award 2006
CardioMEMS Inc announced that it is the recipient of the Frost and Sullivan 2006 Product Innovation of the Year Award. The Award is presented each year to the company that has demonstrated excellence in new products and technologies within its industry. CardioMEMS was recognized for its revolutionary EndoSure Wireless AAA Pressure Measurement System.
KFx Medical Receives 510K Clearance for Rotator Cuff Repair System
KFx Medical, an orthopedic medical device company, announced that it has received FDA Clearance to market its SutureCross™ Knotless Anatomic Fixation System, a minimally invasive percutaneous repair system for rotator cuff tears. The device simplifies the procedure and provides a more anatomical repair than existing techniques.
Asterand Announces Collaberation with Rubicon Genomics
Asterand, a human tissue research company, announced that it has partnered with Rubicon Genomics to discover more sensitive biomarkers for cancer diagnosis. Asterand will supply tissue and biofluid samples, and Rubicon will perform studies with the samples using its proprietary MethylPlex technology™.
HealthMedia Wins 2006 FastTrack Award
HealthMedia, a health care services company that delivers web based tailored behavior support programs, announced that it received the 2006 FastTrack Award. The Washtenaw Development Council presented the award to companies in Washtenaw County that achieved at least 20% average annual growth in the previous three years.
Uptake Medical Closes Series A Round
Uptake Medical Corp., a medical device company, announced that it raised $9 milion in its Series A Round. The company is developing treatments for emphysema and chronic obstructive pulmonary disease (COPD).
NeoGuide Announces FDA Clearance for its Computer-Assisted Colonoscopy System
NeoGuide Systems, Inc., a developer of medical devices to prevent and treat colorectal cancer, announced that it received 510(k) clearance for its colonoscopy system. The colonoscope is designed to enhance physician control, making the procedure faster and less painful for the patient.
Shoulder Arthroscopy Market Continues to Expand
The percentage of rotator cuff procedures performed arthroscopically is forecasted to increase dramatically over the next five years as more positive clinical data continues to be published. KFx Medical plans to launch a product by the end of 2006 that it hopes will further improve clinical outcomes.
CardioMEMS Closes Series C Financing
CardioMEMS, Inc., a developer of wireless pressure sensors used in the treatment of cardiovascular disease, announced that it raised $16 million in its Series C Round. The financing was led by new investor, Medtronic, Inc. The capital will allow the company to expand the launch of its Endosure Sensor, and to begin clinical trials on its second product.
HandyLab and DuPont Announce Partnership
DuPont Qualicon and HandyLab, Inc. have announced an agreement to jointly develop new products for food testing. DuPont will use HandyLab's patented microfluidic technology to develop devices that will simplify the testing process and produce quicker results.
CardioMEMS receives FDA Clearance for its Wireless AAA Pressure Management System
CardioMEMS, Inc received FDA 510(k) approval for its EndoSure Sensor, and will begin selling the system immediately in the U.S. The sensor, which measures intrasac pressure, is implanted during endovascular abdominal aortic aneurysm (AAA) repair.
Indicates a PDF. Download the latest Acrobat Reader.